AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study
The study was assessing a combination of how often patients with advanced, heart-related AL amyloidosis were hospitalised for cardiovascular issues, and death from any cause over a period of time, when compared with placebo.
While anselamimab did not achieve statistical significance for the overall population in the study, the therapy showed clinically meaningful improvement in a sub-group of patients, AstraZeneca said, without giving details of that group.
JPMorgan analyst James Gordon said that he expects the study "failure in all comers to be seen as a minor negative," adding that while AstraZeneca did not give details of the subgroup in which anselamimab worked, he believes the drugmaker may pursue regulatory approval there.
AL amyloidosis, also referred to as light chain or primary amyloidosis, leads to deposits of amyloid protein in the body because of defective plasma cells, and diagnosis is often delayed.
All patients in the AstraZeneca study had received standard of care for the plasma defect, and anselamimab or a placebo was given on top of that.
If left untreated, the accumulation of the deposits, particularly in the heart and kidneys, can progressively impair the quality of life causing organ damage and dysfunction, and lead to heart failure.
"Anselamimab is the first and only investigational fibril depleter to show clinical benefit in AL amyloidosis, and these results underscore its potential to address a critical treatment gap in a prespecified subgroup of patients," said Marc Dunoyer, CEO of AstraZeneca's rare diseases unit, Alexion, which is developing the treatment.
Anselamimab is a type of monoclonal antibody that binds itself to specific targets in the amyloid deposits and helps break them down. The company has forecast peak sales potential of $1 billion to $3 billion for the therapy, against overall annual sales of upwards of $50 billion.
AstraZeneca said it was evaluating the complete data on anselamimab, adding that it plans to share data with health authorities.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
14 hours ago
- Reuters
China's Premier Li proposes global AI cooperation organisation
SHANGHAI, July 26 (Reuters) - Chinese Premier Li Qiang proposed on Saturday establishing a world artificial intelligence cooperation organisation, calling on countries to coordinate development and security of the fast-evolving technology. Speaking at the opening of the annual World Artificial Intelligence Conference in Shanghai, Li called AI a new engine for growth but said governance is fragmented and emphasised the need to step up coordination between countries to form a globally recognised framework for AI. The three-day event brings together industry leaders and policymakers at a time of escalating technological competition between China and the U.S., with AI emerging as a key battleground between the world's two largest economies. Washington has imposed export restrictions on advanced technology to China, including AI chips and chipmaking equipment, citing concerns the technology could enhance China's military capabilities. Despite these restrictions, China has continued making AI breakthroughs that have drawn close scrutiny from U.S. officials. Li said AI technologies were rapidly evolving but that there were constraints, such as the lack of high-end computing chips and restrictions on talent exchange. He called for breaking through bottlenecks for open and coordinated innovation.
Reuters
a day ago
- Reuters
Centene posts surprise loss as medical costs surge, shares slump
July 25 (Reuters) - Centene (CNC.N), opens new tab on Friday posted a surprise quarterly loss, in yet another disappointment for investors in the sector that has suffered a series of setbacks due to rising costs in government-backed insurance plans. Shares of the company tumbled 14.5% in premarket trading, dragging down peers Elevance (ELV.N), opens new tab and Molina Healthcare (MOH.N), opens new tab, which have also warned of elevated costs in government-backed insurance plans. The insurance sector has been under strain for the past two years due to rising medical costs. On one hand, insurers are grappling with increased utilization of behavioral health services, home care, and high-cost drugs, while on the other, the expiration of pandemic-era subsidies and Medicaid protections has shifted enrollment toward sicker members, squeezing their margins. Centene, which largely focuses on government-sponsored plans, posted a medical cost ratio (MCR) of 93% for the quarter, well above Wall Street's expectation of 89.3% and a clear sign of pressure across all business lines. "The medical cost ratio for the quarter was surprisingly high and appeared related to all major lines of business, although its individual exchange business was likely the biggest culprit," said Morningstar analyst Julie Utterback. The quarterly loss was largely attributed to a downward revision in expected 2025 risk adjustment revenue, part of the Affordable Care Act's mechanism to balance costs across insurers. The adjustment, combined with rising Medicaid expenditure drove Centene to a second-quarter adjusted loss of $0.16 per share, versus an expected profit of $0.86, according to data compiled by LSEG. "We are disappointed by our second-quarter results, but we have a clear understanding of trends that have impacted performance, and are working with urgency and focus to restore our earnings trajectory," CEO Sarah London said. Centene said it would provide 2025 earnings expectations on the conference call. The company is in the process of requesting premium increases for Obamacare plans for 2026 to reflect a higher proportion of sicker patients who need more medical care, than it previously expected. Centene expects to be able to take corrective pricing actions for 2026 in states that represent a substantial majority of its membership in those plans.
Reuters
a day ago
- Reuters
HCA raises annual profit forecast on resilient demand for medical care
July 25 (Reuters) - HCA Healthcare (HCA.N), opens new tab raised its 2025 profit forecast on Friday as it expects sustained demand for medical procedures to cushion a hit from U.S. President Donald Trump's potential tariffs. Health insurers have flagged higher-than-anticipated costs in its individual plans that come under the Affordable Care Act, also known as Obamacare, and its Medicaid plans for low-income people. Analysts have said they expect this trend to benefit hospital operators, but warned that proposed federal budget cuts could hit their earnings. HCA earned second-quarter adjusted profit of $6.84 per share, beating analysts' estimates of $6.25 per share, according to data compiled by LSEG. The company expects 2025 profit to be about $25.50 to $27 per share, compared with its previous forecast of $24.05 to $25.85 per share.
